Abstract:Successful hepatocellular carcinoma (HCC) therapy in vivo remains a significant challenge due to the down-regulated expression of the receptors on the surface of tumor cells for compromised active targeting efficiency and cellular uptake of nanoparticles (NPs)-based drug delivery systems (DDSs) and “accelerated blood clearance” and premature unpackaging of NPs in vivo induced by the poly(ethylene glycol)ylation (PEGylation). Inspired by the repeatedly highlighted prolonged blood circulation property of RBCm-camouflaged NPs, we hypothesis that the prolonged blood circulation property resulting from RBCm coating outperforms the active targeting mechanisms of various targeting ligands for enhanced HCC therapy in vivo. Clarification of this hypothesis is therefore of great significance and urgency to break the afore mentioned bottlenecks that hamper the efficient HCC treatment in vivo. For this purpose, we reported in this study the first identification of a determining factor of nanocarriers for enhanced HCC therapy in vivo by the use of the previously fabricated pectin-doxorubicin nanoparticles (PDC-NPs) as a typical example, i.e., the natural RBCm was used as a stealth coating of PDC-NPs for the fabrication of biomimetic DDSs, PDC@RBC-NPs via hypotonic dialysis and mechanical co-extrusion methods. Comprehensive in vitro and in vivo evaluation and comparison of the properties and performance of PDC@RBC-NPs and PDC-NPs were performed in terms of colloidal stability, biosafety, drug release profiles, macrophage escape, anti-HCC effect. The resulting PDC@RBC-NPs outperformed PDC-NPs for HCC therapy in vitro and in vivo. Notably, PDC@RBC-NPs-treated BALB/c nude mice showed a significantly smaller final average tumor volume of 613 mm3 after 16 days than the PDC-NPs-treated group with an average value of 957 mm3. Therefore, the PDC@RBC-NPs developed herein showed great potential for clinical transformations due to the facile preparation and superior therapeutic efficiency against HCC. Most importantly, prolonged blood circulation was identified as a determining factor of nanocarriers instead of active targeting for enhanced HCC therapy in vivo, which could be used to direct the future design and development of advanced DDSs with greater therapeutic efficiency for HCC.

Desirable PEGylation for Improving Tumor Selectivity of Hyaluronic Acid-Based Nanoparticles Via Low Hepatic Captured, Long Circulation Times and CD44 Receptor-Mediated Tumor Targeting.

PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo

Reducing Non-Specific Binding and Uptake of Nanoparticles and Improving Cell Targeting with an Antifouling PEO-b-PγMPS Copolymer Coating

PEGylated hyaluronidase/NIR induced drug controlled release system for synergetic chemo-photothermal therapy of hepatocellular carcinoma

Stepwise targeting and responsive lipid-coated nanoparticles for enhanced tumor cell sensitivity and hepatocellular carcinoma therapy

Enhanced Antitumor Efficacy of Curcumin-Loaded PLGA Nanoparticles Coated with Unique Fungal Hydrophobin

Reduction-sensitive Poly(ethylene Glycol)–polypeptide Conjugate Micelles for Highly Efficient Intracellular Delivery and Enhanced Antitumor Efficacy of Hydroxycamptothecin

Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles

Hydroxycamptothecin (HCPT)-loaded PEGlated lipid–polymer hybrid nanoparticles for effective delivery of HCPT: QbD-based development and evaluation

Dual pH-responsive and CD44 receptor targeted multifunctional nanoparticles for anticancer intracellular delivery

Tumor targeting effect and anti-tumor activity of hydroxycamptothecin loaded stealth niosomes with different polyethylene glycol chain length

Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style.

Hyaluronan-modified nanoparticles for tumor-targeting

Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy

An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery

Hyaluronic Acid Coated Poly(butyl Cyanoacrylate) Nanoparticles As Anticancer Drug Carriers.

Facile Optimization and Evaluation of PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery Using Copolymer Hybrids and Histoculture Drug Response Assays

Effects of Poly(ethylene Glycol) Grafting Density on the Tumor Targeting Efficacy of Nanoparticles with Ligand Modification

Prolonged blood circulation outperforms active targeting for nanocarriers-mediated enhanced hepatocellular carcinoma therapy in vivo

Tumor Microenvironment-Responsive Shell/Core Composite Nanoparticles for Enhanced Stability and Antitumor Efficiency Based on a pH-Triggered Charge-Reversal Mechanism

Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy